skip to main content
Idioma:
Resultados 1 2 3 4 5 next page
Mostrar Somente
Refinado por: nível superior: Revistas revisadas por pares remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R / R DLBCL
LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R / R DLBCL
Material Type:
Artigo 		Adicionar ao Meu Espaço

LOTIS‐5, AN ONGOING PHASE 3 RANDOMIZED STUDY OF LONCASTUXIMAB TESIRINE WITH RITUXIMAB (LONCA‐R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH R / R DLBCL

Carlo‐Stella, C. ; Kwiatek, M. ; Chung, M. ; Móciková, H. ; Bergua‐Burgues, J. M. ; Gao, S. ; Grosicki, S. ; Stathis, A. ; Toupin, D. ; Wang, Y. ; Wang, L. ; Hamadani, M.

Hematological oncology, 2023-06, Vol.41 (S2), p.850-851 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
2
PRELIMINARY FINDINGS OF A PHASE II STUDY OF CHEMO‐FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH‐DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
PRELIMINARY FINDINGS OF A PHASE II STUDY OF CHEMO‐FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH‐DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA
Material Type:
Artigo 		Adicionar ao Meu Espaço

PRELIMINARY FINDINGS OF A PHASE II STUDY OF CHEMO‐FREE COMBINATION OF POMALIDOMIDE, ORELABRUTINIB, RITUXIMAB WITH SEQUENTIAL HIGH‐DOSE METHOREXATE IN NEWLY DIAGNOSED PRIMARY CNS LYMPHOMA

Zhang, Y. ; Chen, C. ; Zhuang, Z. ; Zhao, D. ; Wang, W. ; Wei, C. ; Zhang, W. ; Zhou, D.

Hematological oncology, 2023-06, Vol.41 (S2), p.690-691 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
3
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
ISTH guidelines for treatment of thrombotic thrombocytopenic purpura
Material Type:
Artigo 		Adicionar ao Meu Espaço

ISTH guidelines for treatment of thrombotic thrombocytopenic purpura

Zheng, X. Long ; Vesely, Sara K. ; Cataland, Spero R. ; Coppo, Paul ; Geldziler, Brian ; Iorio, Alfonso ; Matsumoto, Masanori ; Mustafa, Reem A. ; Pai, Menaka ; Rock, Gail ; Russell, Lene ; Tarawneh, Rawan ; Valdes, Julie ; Peyvandi, Flora

Journal of thrombosis and haemostasis, 2020-10, Vol.18 (10), p.2496-2502 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
4
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL
Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL
Material Type:
Artigo 		Adicionar ao Meu Espaço

Obinutuzumab (GA101) compared to rituximab significantly enhances cell death and antibody‐dependent cytotoxicity and improves overall survival against CD20+ rituximab‐sensitive/‐resistant Burkitt lymphoma (BL) and precursor B‐acute lymphoblastic leukaemia (pre‐B‐ALL): potential targeted therapy in patients with poor risk CD20+ BL and pre‐B‐ALL

Awasthi, Aradhana ; Ayello, Janet ; Van de Ven, Carmella ; Elmacken, Mona ; Sabulski, Anthony ; Barth, Matthew J. ; Czuczman, Myron S. ; Islam, Humayun ; Klein, Christian ; Cairo, Mitchell S.

British journal of haematology, 2015-12, Vol.171 (5), p.763-775 [Periódico revisado por pares]

England

Texto completo disponível

Citações Citado por
5
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Material Type:
Artigo 		Adicionar ao Meu Espaço

Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience

Salles, Gilles ; Barrett, Martin ; Foà, Robin ; Maurer, Joerg ; O’Brien, Susan ; Valente, Nancy ; Wenger, Michael ; Maloney, David G.

Advances in therapy, 2017-10, Vol.34 (10), p.2232-2273 [Periódico revisado por pares]

Cheshire: Springer Healthcare

Texto completo disponível

Citações Citado por
6
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)
Material Type:
Artigo 		Adicionar ao Meu Espaço

Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2)

Charles, Pierre ; Terrier, Benjamin ; Perrodeau, Élodie ; Cohen, Pascal ; Faguer, Stanislas ; Huart, Antoine ; Hamidou, Mohamed ; Agard, Christian ; Bonnotte, Bernard ; Samson, Maxime ; Karras, Alexandre ; Jourde-Chiche, Noémie ; Lifermann, François ; Gobert, Pierre ; Hanrotel-Saliou, Catherine ; Godmer, Pascal ; Martin-Silva, Nicolas ; Pugnet, Grégory ; Matignon, Marie ; Aumaitre, Olivier ; Viallard, Jean-François ; Maurier, François ; Meaux-Ruault, Nadine ; Rivière, Sophie ; Sibilia, Jean ; Puéchal, Xavier ; Ravaud, Philippe ; Mouthon, Luc ; Guillevin, Loïc

Annals of the rheumatic diseases, 2018-08, Vol.77 (8), p.1143-1149 [Periódico revisado por pares]

England: BMJ Publishing Group LTD

Texto completo disponível

Citações Citado por
7
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial
Material Type:
Artigo 		Adicionar ao Meu Espaço

Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial

Matasar, Matthew J ; Capra, Marcelo ; Özcan, Muhit ; Lv, Fangfang ; Li, Wei ; Yañez, Eduardo ; Sapunarova, Katya ; Lin, Tongyu ; Jin, Jie ; Jurczak, Wojciech ; Hamed, Aryan ; Wang, Ming-Chung ; Baker, Ross ; Bondarenko, Igor ; Zhang, Qingyuan ; Feng, Jifeng ; Geissler, Klaus ; Lazaroiu, Mihaela ; Saydam, Guray ; Szomor, Árpád ; Bouabdallah, Krimo ; Galiulin, Rinat ; Uchida, Toshiki ; Soler, Lidia Mongay ; Cao, Anjun ; Hiemeyer, Florian ; Mehra, Aruna ; Childs, Barrett H ; Shi, Yuankai ; Zinzani, Pier Luigi

The lancet oncology, 2021-05, Vol.22 (5), p.678-689 [Periódico revisado por pares]

England: Elsevier Ltd

Texto completo disponível

Citações Citado por
8
Terapia com Rituximabe para síndrome nefrótica idiopática de início na infância: experiência de um centro terciário português
Terapia com Rituximabe para síndrome nefrótica idiopática de início na infância: experiência de um centro terciário português
Material Type:
Artigo 		Adicionar ao Meu Espaço

Terapia com Rituximabe para síndrome nefrótica idiopática de início na infância: experiência de um centro terciário português

Gomes, Rita ; Mosca, Sara ; Bastos-Gomes, Mariana ; Correia-Costa, Liane ; Rocha, Liliana ; Teixeira, Ana ; Costa, Teresa ; Sameiro-Faria, Maria ; Matos, Paula ; Mota, Conceição

Jornal Brasileiro de nefrologia, 2023-09, Vol.45 (3), p.326-334 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por
9
SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL
SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL
Material Type:
Artigo 		Adicionar ao Meu Espaço

SMART STOP: A PHASE II CLINICAL TRIAL OF LENALIDOMIDE, TAFASITAMAB, RITUXIMAB, AND ACALABRUTINIB ALONE AND WITH RESPONSE ADAPTED CHEMOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED DLBCL

Westin, J. ; Strati, P. ; Chihara, D. ; Pulsifer, B. ; Tom, J. ; Davis, R. E. ; Lee, H. J. ; Nair, R. ; Rodriguez, A. ; Hagemeister, F. ; Flowers, C. ; Nastoupil, L. ; Feng, L. ; Green, M. ; Fayad, L. ; Iyer, S. ; Ahmed, S. ; Steiner, R.

Hematological oncology, 2023-06, Vol.41 (S2), p.837-838 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
10
INFERIOR OUTCOMES WITH POLATUZUMAB VEDOTIN, BENDAMUSTINE AND RITUXIMAB FOR TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER >1 PRIOR LINE OF THERAPY
INFERIOR OUTCOMES WITH POLATUZUMAB VEDOTIN, BENDAMUSTINE AND RITUXIMAB FOR TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER >1 PRIOR LINE OF THERAPY
Material Type:
Artigo 		Adicionar ao Meu Espaço

INFERIOR OUTCOMES WITH POLATUZUMAB VEDOTIN, BENDAMUSTINE AND RITUXIMAB FOR TREATMENT OF RELAPSED/REFRACTORY LARGE B‐CELL LYMPHOMA AFTER >1 PRIOR LINE OF THERAPY

Northend, M. ; Wilson, W. ; Ediriwickrema, K. ; Osborne, W. ; Auer, R. ; Burton, C. ; Davies, A. ; El‐Sharkawi, D. ; Fox, C. ; Karim, R. ; Kuhnl, A. ; McKay, P. ; Peng, Y. Y. ; Phillips, E. ; Phillips, N. ; Townsend, W.

Hematological oncology, 2023-06, Vol.41 (S2), p.716-717 [Periódico revisado por pares]

Chichester: Wiley Subscription Services, Inc

Texto completo disponível

Citações Citado por
Resultados 1 2 3 4 5 next page

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

Mostrar Somente

  1. Recursos Online (21.356)

Refinar Meus Resultados

Tipo de Recurso 

  1. Artigos  (22.598)
  2. Book Chapters  (25)
  3. Anais de Congresso  (10)
  4. Web Resources  (2)
  5. magazinearticle  (1)
  6. Mais opções open sub menu

Data de Publicação 

De até
Refinar
  1. Antes de2001  (173)
  2. 2001Até2006  (1.978)
  3. 2007Até2012  (5.374)
  4. 2013Até2019  (8.460)
  5. Após 2019  (6.648)
  6. Mais opções open sub menu

Idioma 

  1. Inglês  (21.437)
  2. Japonês  (2.331)
  3. Francês  (412)
  4. Espanhol  (271)
  5. Alemão  (224)
  6. Russo  (182)
  7. Português  (67)
  8. Coreano  (56)
  9. Italiano  (53)
  10. Chinês  (40)
  11. Polonês  (32)
  12. Húngaro  (29)
  13. Tcheco  (28)
  14. Norueguês  (24)
  15. Croatian  (11)
  16. Turco  (5)
  17. Persa  (3)
  18. Indonésio  (2)
  19. Islândico  (2)
  20. Sueco  (2)
  21. Mais opções open sub menu

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.